Herpes simplex virus-1 (HSV-1) replication in cancer cells leads to their destruction (viral oncolysis) and has been under investigation as an experimental cancer therapy in clinical trials as single agents, and as combinations with chemotherapy. Cellular responses to chemotherapy modulate viral replication, but these interactions are poorly understood. To investigate the effect of chemotherapy on HSV-1 oncolysis, viral replication in cells exposed to 5-fluorouracil (5-FU), irinotecan (CPT-11), methotrexate (MTX) or a cytokine (tumor necrosis factor-a (TNF-a)) was examined. Exposure of colon and pancreatic cancer cells to 5-FU, CPT-11 or MTX in vitro significantly antagonizes both HSV-1 replication and lytic oncolysis. Nuclear factor-kB (NF-kB) activation is required for efficient viral replication, and experimental inhibition of this response with an IkBa dominant-negative repressor significantly antagonizes HSV-1 replication. Nonetheless, cells exposed to 5-FU, CPT-11, TNF-a or HSV-1 activate NF-kB. Cells exposed to MTX do not activate NF-kB, suggesting a possible role for NF-kB inhibition in the decreased viral replication observed following exposure to MTX. The role of eukaryotic initiation factor 2a (eIF-2a) dephosphorylation was examined; HSV-1-mediated eIF-2a dephosphorylation proceeds normally in HT29 cells exposed to 5-FU, CPT-11 or MTX. This report demonstrates that cellular responses to chemotherapeutic agents provide an unfavorable environment for HSV-1-mediated oncolysis, and these observations are relevant to the design of both preclinical and clinical studies of HSV-1 oncolysis.
INTRODUCTION
Given the limitations of current treatment options for solid tumor metastases, there remains strong rationale to develop novel therapies such as oncolysis by replicating viruses. We have previously examined regulation of herpes simplex virus 1 (HSV-1) at the molecular level, and used this information to (i) genetically engineer HSV-1 mutants that when introduced intravascularly into the liver replicate preferentially in liver tumors rather than normal cells; [1] [2] [3] (ii) express therapeutic transgenes such as prodrug activation genes and antiangiogenesis genes; 4, 5 and (iii) enhance survival of animals with diffuse liver tumors following intravascular HSV-1 administration. [4] [5] [6] Clinical trials of HSV-1 oncolytic mutants to treat unresectable and refractory malignancies are currently being conducted and involve administration of HSV-1 before, during or after administration of chemotherapy agents. [7] [8] [9] Little has been published regarding chemotherapy-induced modulation of cellular pathways that are intimately linked to viral replication, and we therefore embarked on studies to examine the interactions.
Viruses have evolved numerous mechanisms to achieve robust viral replication by evasion or compensation for host anti-viral strategies, such as those involved in induction of apoptosis, cytokine production and anti-viral pathways activated by double-stranded RNA. For example, host cell double-stranded RNA-activated protein kinase (PKR) is a central enzyme involved in anti-viral activity, and has been shown to modulate replication of many viruses. 10 The importance of PKR in controlling viral infections is underscored by the observation that many viruses use strategies to bypass PKR responses, such as inhibition of PKR activation, sequestration of double stranded RNA, inhibition of PKR responses, synthesis of PKR pseudosubstrates, activation of antagonist phosphatases and PKR degradation.
10-12 PKR induces nuclear factor-kB (NF-kB) activation and independently triggers a translational block through phosphorylation of eIF-2a. 11 This could markedly attenuate HSV-1 replication; however, the product of an HSV-1 gene g 1 34.5 interacts with the cellular protein phosphatase-1a to dephosphorylation eIF-2a and enable translation. 11, [13] [14] [15] To improve clinical studies of chemotherapy and HSV-1, it is important to understand how modulation of PKR by chemotherapy affects HSV-1 replication and oncolysis.
As another example of the interactions between chemotherapy and HSV-1 oncolysis, the dimeric transcription factor NF-kB regulates expression of genes involved in immune responses, inflammatory responses and apoptotic responses. 16, 17 Activation of NF-kB occurs in response to stresses including radiation and chemotherapy; by agents such as tumor necrosis factor-a (TNF-a), interleukin-1, lipopolysaccharide and phorbol ester; and by inducers of endoplasmic reticulum overload. [18] [19] [20] [21] And viruses have evolved mechanisms to modulate NF-kB activity to enhance expression of viral genes. 22, 23 As such, cell modulation of NF-kB in response to chemotherapy may alter cell susceptibility to lytic viral replication. In this study, we investigated the effect of chemotherapy on HSV-1 oncolysis using agents that are commonly used to treat gastrointestinal malignancies.
MATERIALS AND METHODS

Cells and viruses
Vero (African Monkey kidney), HT29 and SW620 (human colon carcinoma), Capan-2 (human pancreatic cancer) and 293 (human kidney) were obtained from American Type Culture Collection (Rockville, MD, USA). ICP (infected cell protein) 0-transformed Vero cells (0-28) and ICP4-transformed Vero cells (E5) were kindly provided by E Antonio Chiocca (Massachusetts General Hospital, Boston, MA, USA). ICP27-transformed Vero cells (V27) were kindly provided by David Knipe (Harvard Medical School, Boston, MA, USA). Cells were propagated in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 100 U ml À 1 penicillin and 100 mg ml À 1 streptomycin. ICP6-defective HSV-1 mutant (hrR3) 24 was kindly provided by Sandra Weller (University of Connecticut, Farmington, CT, USA). ICP0-defective HSV-1 mutant (7134) 19 and ICP4-defective HSV-1 mutant (gal4) 23 were kindly provided by E Antonio Chiocca (Massachusetts General Hospital). ICP27-defective HSV-1 mutant (d27) 25 were kindly provided by David Knipe. Wild-type HSV-1 strain KOS 26 was kindly provided by Donald Coen (Harvard Medical School). g 1 34.5-Defective HSV-1 mutant (R3616) 13 was kindly provided by Bernard Roizman (University of Chicago, Chicago, IL, USA). Heat inactivation of viruses was performed as described. 27 The drugs used in cell culture studies were TNF-a (Sigma, St Louis, MO, USA), methotrexate (MTX; Ben Vanue Laboratories, Bedford, OH, USA), 5-fluorouracil (5-FU; Pharmacia and Upjohn, Kalamazoo, MI, USA) and irinotecan (CPT-11; Pharmacia and Upjohn).
The recombinant adenovirus vectors used in this study were replicationdefective Ad5-based vectors constructed with the transgene expression driven by the CMV early/intermediate promoter/enhancer. All vectors were expanded in 293 cells and purified and titered as described previously. 28 The vector Ad.CMV.IkBa expresses the super-repressor (SR) form of IkBa that is mutated at serine residues 32 and 36 and functions as a potent and specific repressor of NF-kB-mediated events. 28, 29 The control vector Ad.CMV3, generously provided by JA Roth (University of Texas MD Anderson Cancer Center, Houston, TX, USA), contains a CMV promoter similar to Ad.CMV.IkBa but lacks a transgene insert.
In vitro viral cytotoxicity and replication assays Viral replication assays were performed by infecting 10 6 cells with HSV-1 for 2 h, at which time unabsorbed virus was removed by washing with a glycine-saline solution (pH ¼ 3.0). At 0, 8, 16, 24, 32 and 40 h after infection, the supernatant and cells were exposed to three freeze/thaw cycles to release virions and titered on Vero cells or 0-28 cells. Viral cytotoxicity was determined as described previously. 1 Briefly, 5000 cells per well were plated onto 96-well plates and grown for 36 h. Cells were then infected with either KOS or HSV-1 mutants using multiplicity of infection (MOI) values ranging from 0.001 to 10. The number of viable cells was determined using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. All experiments were performed in quadruplicate.
Electrophoretic mobility shift assay for NF-kB activation pepstain and 2.5 mg ml À 1 leupeptin). Nuclear pellets were collected at 3000 r.p.m. (4 1C) to which 100 ml of capillary electrophoresis buffer was added. After centrifugation at 3000 r.p.m. (4 1C), the pellet was resuspended in two pellet volumes of NE buffer (20 mM Tris (pH ¼ 8.0), 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM ethylenediaminetetraacetic acid and 25% glycerol) with proteinase inhibitors, and then added 60 ml of 5 M NaCl. The soluble protein was released by centrifugation (20 min at 14 000 r.p.m.), and stored at À 80 1C. The amount of protein in the supernatant was quantified using a BCA Protein Assay Kit (Pierce Chemical, Rockford, IL, USA). The DNA probe used contains an NF-kB site (underlined) from the H-2k b gene (5 0 -CAGGGCTGGGGATTCCCATCTCCACAGTTTCACTTC-3 0 ). 28 In all, 10 mg of nuclear extracts were preincubated with 1 mg of 30 Purification of bacteria-expressed PKR and eIF-2a
Production of PKR and eIF-2a was performed as described previously. 6 In brief, Escherichia coli BL21 cells harboring the pGEX-PKR and pQE-eIF-2a expression vectors (kindly provided by Bryan RG Williams, Lerner Research Institute, Cleveland, OH, USA) were grown overnight in 50 ml Luria-Bertani broth containing 50 mg ml À 1 ampicillin. Following 1:10 dilution in fresh Luria-Bertani broth, cells were grown for 3 h to an optical density of 0.8, at which time isopropyl-1-thio-b-D-galactopyranoside was added to a concentration of 1 mM for an additional 4 h. Bacteria were pelleted and used for the fusion protein purification. To purify the His-tagged eIF-2a protein, a His Á Bind Purification Kit (Novagen, Madison, WI, USA) was used following the manufacturer's instructions. To purify the glutathione S-transferase (GST)-tagged PKR, a GST Á Bind Purification Kit (Novagen) was used according to the manufacturer's instructions.
In vitro phosphorylation assays
The PKR autophosphorylation assay was performed as follows: HT29 cells were harvested at 24 h after treatment with 5-FU (100 mM), CPT-11 (1 mM), MTX (25 mM) and TNF-a (10 ng ml À 1 ). The cells were rinsed with PBS, resuspended in lysis buffer containing 10 mM HEPES (pH ¼ 7.6), 150 mM NaCl, 10 mM MgCl 2 , 0.2% Triton X-100, 10% glycerol, 0.5 mM phenylmethylsulfonyl fluoride and 2 mM benzamide, placed on ice for 30 min and subjected centrifugation to remove nuclei. The cell lysates were reacted with [g-32 P]ATP (100 mCi per sample) for 30 min at 32 1C, precleared with protein A-agarose (Roche Diagnostics Corp., Indianapolis, IL, USA) and reacted with 1 mg of antibody to PKR (K-17) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or without the PKR antibody for negative control. These complexes were precipitated using protein-A agarose, rinsed with RIPA buffer (PBS containing 0.25% NP-40, 0.5% sodium deoxycholate and 0.1% sodium dodecyl sulfate), solubilized in buffer C (20 mM Tris-HCl (pH ¼ 7.0), 50 mM KCl and 2 mM MgCl 2 ), electrophoretically separated in a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and subjected to autoradiography. For eIF-2a phosphorylation assay, 2 ml of purified eIF-2a protein (0.32 mg ml ) was added to the kinase reaction (2 ml of cell lysate (0.32 mg ml À 1 ), 7 ml of buffer C and 1 ml of [g-32 P]ATP (10 mCi ml À 1 )). These reactions were incubated at 32 1C for 40 min before the addition of 2 Â SDS loading buffer (12 ml) was added to each sample before boiling, separation by 10% SDS-PAGE and autoradiography. The PKR-32 P or eIF-2a- 
In vitro eIF-2a dephosphorylation assays
Confluent 100 mm plate of HT29 cells were harvested 24 h after treatment with chemotherapeutic drugs (5-FU (100 mM), CPT-11 (1 mM), MTX (25 mM) and TNF-a (10 ng ml À 1 )) in the presence or absence of HSV-1 KOS (MOI ¼ 1) infection. Cells were rinsed once with PBS and added to 100 ml of cell lysate buffer and placed on ice for 30 min and then centrifuged. The amount of protein in supernatant was quantified using a BCA Protein Assay Kit (Pierce Chemical). Purified eIF-2a protein (12.5 ml; 0.32 mg ml
) was reacted with GST-PKR protein (12.5 ml; 0.32 mg ml À 1 ) in 38 ml of buffer C and 7 ml of [g-32 P]ATP (10 mCi ml À 1 ) in a final volume of 70 ml for 40 min at 32 1C to yield phosphorylated eIF-2a. After 40 min at 32 1C, 8 ml of phosphorylated eIF-2a (eIF-2a-32 P) was mixed with 10 ml of the lysates and 7 ml of buffer C. Following incubation at room temperature for different time intervals, 10 ml aliquots were removed at specific time point, mixed with 2 Â SDS loading buffer (10 ml), boiled for 3 min and analyzed by SDS-PAGE. The 32 P remaining in eIF-2a- 32 P was quantified by an image analyzer (LabWorks 4.0).
Statistical analysis
The mean values of the cell survival rates from the cytotoxicity assay, viral yields from the viral replication assay and optical density from the EMSA of NF-kB, PKR/eIF-2a phosphorylation assay or eIF-2a dephosphorylation Inhibition of HSV-1 oncolysis by chemotherapy Y Kulu et al assay were compared by two-sided Student's t-test. Statistical analysis and calculation of the regression coefficients were performed using StatView software (SAS Institute, Cary, NC, USA).
RESULTS
Chemotherapy-induced cytotoxicity inhibits viral replication
We initially determined the relationship between concentration of chemotherapy agents and cytoxicity in colon and pancreatic carcinoma cells. We included TNF-a in these studies because of the known effect of TNF-a on viral replication, NF-kB and PKR. As expected, increasing drug concentrations were associated with increasing cytotoxicity for all cell lines (Figure 1a) . We then infected these cells with HSV-1 in three conditions: no chemotherapy, a low concentration that produced no cytotoxicity alone and a higher concentration that induced cytotoxicity alone. In all three cell lines, cytotoxicity induced by HSV-1 alone was no different than cyotoxicity induced by HSV-1 combined with a low concentration of chemotherapy or TNF-a (Figure 1b ). Exposure to a higher concentration of chemotherapy combined with HSV-1 infection did not produce more cytotoxicity than either HSV-1 alone or drug alone, suggesting that chemotherapy agents antagonized viral oncolysis. We observed identical results with other HSV-1 mutants, including 7134 (ICP0-defective) and hrR3 (ICP6-defective) (data not shown). To investigate the relationship between viral replication and cellular responses to chemotherapy, we used a burst assay to measure HSV-1 replication in cells treated with TNF-a, 5-FU, CPT-11 and MTX. KOS replication is significantly inhibited by all of the drugs (Figure 1c) . Similar results were observed with HSV strains 7134 and hrR3 (data not shown).
NF-kB activation is required for efficient HSV-1 replication The NF-kB pathway provides an attractive target to viral pathogens; many viruses exploit the antiapoptotic properties of NF-kB to evade host defense mechanisms. 16 Beginning at around 3 h after infection, KOS-infected HT29 cells demonstrate inducible NF-kB activation compared with mock-infected cells (Figure 2a ). NF-kB nuclear translocation increases over time, leading a maximum at 24 h. HT29 cells infected with HSV-1 mutants that are defective in ICP0, ICP4 and ICP27 (7134, gal4 and d27, respectively) do not activate NF-kB as strongly as cells infected with KOS. In contrast, the ICP6-defective HSV-1 mutant (hrR3) and g 1 34.5-defective HSV-1 mutant (R3616) induce NF-kB activation as effectively as cells infected with KOS.
To further examine the relationship between HSV-1 replication and NF-kB activation, we used a serine-mutated form of IkBa, which does not undergo phosphorylation at key sites and is therefore not targeted for polyubiquitination and degradation by the proteosomes. 17, 29 Adenoviral-mediated delivery of a gene encoding IkBa-SR effectively blocks NF-kB. 17, 29 We first confirmed that infection of HT29 cells with a replication-defective adenovirus Differential effects of chemotherapeutic agents on NF-kB activation Exposure of colon cancer cells to 5-FU, CPT-11 and TNF-a induces NF-kB activation in a manner that is both time-dependent and dose-dependent (Figures 3a and b) . In contrast, exposure to MTX does not activate NF-kB. We examined the effect of chemotherapeutic agents on HSV-1-induced NF-kB activation. Treatment with TNF-a, 5-FU or CPT-11 during KOS infection does not alter NF-kB activation compared with KOS infection alone (Figure 3c ). This finding suggests that the mechanism by which 5-FU and CPT-11 inhibits HSV-1 replication is independent of their effects on NF-kB activation. The mechanism by which MTX inhibits viral replication may be through its ability to inhibit NF-kB activation.
Chemotherapeutic agents induce PKR/eIF-2a phosphorylation Eukaryotic viruses and their multicellular hosts have coevolved complex interrelationships to permit virus reproduction without destruction of the host. 10, 11 A central enzyme involved in anti-viral activity is the PKR. 10, 11 One of the major biological functions of PKR is to regulate protein translation through phosphorylation of eIF-2a.
11
HSV-1 g 1 34.5 expression results in eIF-2a dephosphorylation, which aids efficient HSV-1 replication, 13 and we have previously demonstrated the importance of eIF-2a dephosphorylation for viral oncolysis. 6 Accordingly, we measured eIF-2a phosphorylation induced by PKR in response to TNF-a, 5-FU, CPT-11 or MTX. Protein lysates of HT29 cells treated with these agents were examined for their ability to phosphorylate PKR, phosphorylate eIF-2a and dephosphorylate eIF-2a in the presence or absence of HSV-1 infection (KOS). KOS stimulates PKR phosphorylation, as do each of the agents; however, the PKR phosphorylation by KOS infection is unchanged by TNF-a, 5-FU, CPT-11 or MTX (Figure 4a) . Similarly, eIF-2a phosphorylation observed in response to each of the agents is unchanged (Figure 4b ). CPT-11 and MTX induce some eIF-2a dephosphorylation activity, but overall dephosphorylation activity in response to HSV-1 infection is not altered by any of the agents (Figure 4c) . Thus, chemotherapy induces PKR and eIF-2a phosphorylation, but HSV-1-mediated dephosphorylation of these regulatory proteins remains active. Overall, these results suggest that HSV-1-induced PKR phosphorylation and eIF-2a 
DISCUSSION
Oncolytic HSV-1 mutants are now under evaluation in clinical trials in patients with advanced malignancy including gastrointestinal malignancies. [31] [32] [33] [34] Although mechanisms of interaction between chemotherapy and viral replication are poorly understood, NF-kB activation is required for robust HSV-1 replication, and moreover, various chemotherapeutic agents and HSV-1 infection independently induce NF-kB activation. Thus, we were initially buoyed with the possibility that the combination of chemotherapy and HSV-1 oncolysis could act synergistically through augmented viral replication and oncolysis. At a minimum, we reasoned that cells in which NF-kB is activated in response to chemotherapy would be more susceptible to HSV-1 oncolysis. We thus found it of significance and interest that pretreatment of cells with specific chemotherapeutic agents simultaneously reduces viral replication and antagonizes viral oncolysis.
Herpesvirus-, adenovirus-, measelsvirus-, vaccinavirus-or reovirus-based oncolytic vectors have previously been evaluated in combination with various chemotherapeutic agents against different human cancers. [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] Different interactions have been observed in these studies, and appear to depend on the mechanism of action of the specific chemotherapeutic agent, the type of cancer and the specific oncolytic virus. In some preclinical studies, the combination of an oncolytic virus with chemotherapeutic agents resulted in an enhanced oncolytic effect. Some combinations have already been translated into clinical trials. 43, 50, 51 However, Cheema et al. 52 demonstrated that CPT-11 inhibits G47D (a g 1 34.5-, ICP6 and a47-defective HSV-1 mutant) replication in U87 glioma cells even at low doses. Similarly, doxorubicin, etoposide and cisplatin were shown to inhibit the replication of G47D in LNCaP prostate cancer cells. 53 Other studies have shown that the replication of the HSV-1 mutants R3616 and hrR3 in Capan-1, PaCa-2 and SW1990 pancreatic cancer cells is decreased after treatment with gemcitabine. 49 Gutermann et al. demonstrated that 5-FU potentiates the efficacy of herpesvirus oncolysis mediated by NV1066 (single copy of ICP0, ICP4 and g 1 34.5 deleted) in human pancreatic cancer cells. 54 However, in the study of Eisenberg et al., 54 the cells were treated with a different HSV-1 mutant, were exposed to 5-FU only for 6 h, with a 5-FU dose up to 100-fold less compared with our study.
Although chemotherapy agents simultaneously induced NF-kB activation and inhibited viral replication, the mechanism by which MTX treatment inhibits viral replication may be via inhibition of NF-kB activation. Majumdar et al. 18 demonstrated in a series of experiments that MTX suppresses NF-kB activation through -11) or methotrexate MTX for 24 h, after which time equal amounts (10 mg) of nuclear extracts from the cells were prepared and analyzed by electrophoretic mobility shift assay (EMSA). (b) HT29 cells were treated with 10 ng ml À 1 TNF-a, 100 mM 5-FU, 1 mM CPT-11 and 25 mM MTX for up to 36 h, and nuclear extracts were prepared and analyzed by EMSA. Negative control: medium (Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) and antibiotics) alone. (c) HT29 cells were treated with 10 ng ml À 1 TNF-a, 100 mM 5-FU, 1 mM CPT-11 and 25 mM MTX in the presence or absence of herpes simplex virus 1 (HSV-1) KOS infection for 24 h, and nuclear extracts were prepared and analyzed by EMSA. Negative control: medium (DMEM with 10% FBS and antibiotics) alone. Positive control: nuclear extracts from HT29 that were treated with 10 ng ml À 1 TNF-a for 24 h. The density of each band was determined using the UVP image software, and results are shown as mean ± s.d. in the graph. the release of adenosine. This concept is supported by our observation that inhibition of NF-kB activation by the IkBa-SR inhibits viral replication. However, other mechanisms may also be operant. MTX is an antifolate and its primary cellular target is dihydrofolate reductase, which catalyzes the reduction of folate and 7,8 dihydrofolate to 5,6,7,8 tetrahydrofolate. 55 An essential requirement for both cellular and viral DNA synthesis is a large expansion in the pools of deoxyribonucleoside triphosphates. 55, 56 It is conceivable that a lowering of intracellular nucleotide pools observed in response to MTX is partially responsible for the inhibition of viral replication. 57, 58 Similarly, the pyrimidine antimetabolite 5-FU interferes with DNA synthesis and causes an imbalance of the intracellular deoxynucleotide triphosphate pools 59 and modulates cell cycle progression. 60 Furthermore,
CPT-11 and its active metabolite SN-38 bind to and inhibits irreversibly the enzyme DNA-topoisomerase I and causes doublestranded DNA breaks during DNA replication. 61, 62 These imbalances in cellular function following treatment of 5-FU and CPT-11 may interfere with and negatively affect HSV-1 replication.
NF-kB induction is critical for expression of not only multiple genes critical for cell survival but also for expression of specific viral genes. Many viruses have evolved mechanisms to target the NF-kB pathway to facilitate cell survival, viral replication and evasion of immune responses. 16, 20 In addition, some viruses use the NF-kB pathway either for its antiapoptotic properties to evade the host defense mechanisms or to trigger apoptosis as a mechanism of virus spread. 16 HSV-1 modulates the host cell environment to promote its own propagation. 6, 63 We observed that wild-type HSV-1 induces NF-kB activation, whereas some HSV-1 mutants do not induce NF-kB activation, and this observation is consistent with earlier reports. [63] [64] [65] The persistent nuclear translocation of NF-kB in HSV-1-infected cells coincides with increased binding of NF-kB to specific DNA response elements. 64 Whether the increased DNA-bound NF-kB reflects increased activity and subsequent transcription of target genes is not clear. Patel et al. 64 reported decreased expression of an NF-kBinducible reporter gene following virus-induced NF-kB activation, whereas others report increased NF-kB-dependent gene transcription. 63, 65 Here we present our observations that HSV-1 induces a persistent activation of NF-kB in HT29 colon carcinoma cells, beginning at around 3 h post-infection, and that regulatory functions of ICP0, ICP4 or ICP27 are required for this robust NF-kB nuclear translocation. Replication of mutants defective in these immediate-early genes is markedly attenuated compared with wild-type KOS replication. However, even replication of KOS is attenuated with experimental inhibition of NF-kB activation. NF-kB activation appears to be critically important for robust HSV-1 replication.
The importance of PKR as a host anti-viral strategy is highlighted by the observation that many viruses possess mechanisms to counteract its action.
10,11 eIF-2a is normally phosphorylated by PKR in response to HSV-1 infection. Phosphorylated eIF-2a leads to attenuated viral replication as a result of inhibition of protein translation. HSV-1 g 1 34.5 interacts with protein phosphatase-1a to dephosphorylate eIF-2a to block the shutoff of protein synthesis and permit robust viral replication. 11 We and others have previously demonstrated that reduced eIF-2a dephosphorylation during HSV-1 infections is associated with attenuated viral replication. 6, 14 In this study, we observed that eIF-2a dephosphorylation in response to HSV-1 infection proceeds regardless of exposure to chemotherapeutic agents.
Although NF-kB activation appears to be an indispensable cellular response for robust HSV-1 replication, and chemotherapeutic agents such as 5-FU and CPT-11 induce NF-kB activation, these agents inhibit HSV-1 replication. Cellular responses to chemotherapy provide an unfavorable environment for HSV-1-mediated oncolysis. These observations are relevant to the design of both preclinical and clinical studies of HSV-1 oncolysis.
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